These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 24893886)

  • 1. The normal and pathologic roles of the Alzheimer's β-secretase, BACE1.
    Kandalepas PC; Vassar R
    Curr Alzheimer Res; 2014; 11(5):441-9. PubMed ID: 24893886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology.
    Cai Y; Zhang XM; Macklin LN; Cai H; Luo XG; Oddo S; Laferla FM; Struble RG; Rose GM; Patrylo PR; Yan XX
    Neurotox Res; 2012 Feb; 21(2):160-74. PubMed ID: 21725719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.
    Ly PT; Wu Y; Zou H; Wang R; Zhou W; Kinoshita A; Zhang M; Yang Y; Cai F; Woodgett J; Song W
    J Clin Invest; 2013 Jan; 123(1):224-35. PubMed ID: 23202730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BACE1 structure and function in health and Alzheimer's disease.
    Cole SL; Vassar R
    Curr Alzheimer Res; 2008 Apr; 5(2):100-20. PubMed ID: 18393796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development.
    Zhang XM; Cai Y; Xiong K; Cai H; Luo XG; Feng JC; Clough RW; Struble RG; Patrylo PR; Yan XX
    Eur J Neurosci; 2009 Dec; 30(12):2271-83. PubMed ID: 20092570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
    Barão S; Moechars D; Lichtenthaler SF; De Strooper B
    Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau deletion reduces plaque-associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
    Peters F; Salihoglu H; Pratsch K; Herzog E; Pigoni M; Sgobio C; Lichtenthaler SF; Neumann U; Herms J
    EMBO J; 2019 Dec; 38(23):e102345. PubMed ID: 31701556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease.
    Sadleir KR; Kandalepas PC; Buggia-Prévot V; Nicholson DA; Thinakaran G; Vassar R
    Acta Neuropathol; 2016 Aug; 132(2):235-256. PubMed ID: 26993139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis.
    Zhao J; Fu Y; Yasvoina M; Shao P; Hitt B; O'Connor T; Logan S; Maus E; Citron M; Berry R; Binder L; Vassar R
    J Neurosci; 2007 Apr; 27(14):3639-49. PubMed ID: 17409228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential.
    Vassar R; Kovacs DM; Yan R; Wong PC
    J Neurosci; 2009 Oct; 29(41):12787-94. PubMed ID: 19828790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease.
    Tomita T
    Adv Biol Regul; 2017 May; 64():33-38. PubMed ID: 28082052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques.
    Kandalepas PC; Sadleir KR; Eimer WA; Zhao J; Nicholson DA; Vassar R
    Acta Neuropathol; 2013 Sep; 126(3):329-52. PubMed ID: 23820808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
    Vassar R
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level.
    Sadleir KR; Eimer WA; Cole SL; Vassar R
    Mol Neurodegener; 2015 Jan; 10():1. PubMed ID: 25567526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
    Hook G; Yu J; Toneff T; Kindy M; Hook V
    J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status.
    Evin G; Hince C
    Drugs Aging; 2013 Oct; 30(10):755-64. PubMed ID: 23842796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.